MedTrace Logo

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT04551885 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-09-21

No results posted yet for this study

Summary

This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

FT516

Experimental Interventional Therapy

DRUG

Avelumab

Monoclonal antibody

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

IL-2

Biologic response modifier

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2023-08-11
Completion
2023-08-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04551885 on ClinicalTrials.gov